Tech AI LatestIsomorphic Labs raises $5 billion Series C, then signs an oncology deal with MSD
Isomorphic Labs raised $5 billion on 17 November 2026 in a round co-led by Greenoaks and Sequoia, then signed a cancer drug research deal with MSD.
Summary
Isomorphic Labs, the Alphabet drug discovery company led by Demis Hassabis, announced a $5 billion Series C on 17 November 2026, co-led by Greenoaks and Sequoia Capital with Andreessen Horowitz joining. It did not disclose a valuation. Two days later Merck, known as MSD outside the US and Canada, signed a research collaboration with the company on a cancer target. Isomorphic has not yet put a drug into human trials.